Análisis prospectivo del sector servicios caso empresa limpia todo S.A.S

Limpia Todo S.A.S es una empresa colombiana prestadora de servicios integrales de limpieza, pertenece al sector económico de servicios de aseo. Su sede principal está en la ciudad de Bogotá

Tratamiento con fludrocortisona en una paciente con cerebro perdedor de sal asociado a meningitis por criptococosis

Introducción: el cerebro perdedor de sal (CPS) es un síndrome de etiología confusa, responsable de un trastorno hidroelectrolítico de hiponatremia hipovolémica significativa, descrito en pacientes con afección del sistema nervioso central (SNC) por traumas o infecciones. Objetivo: describir el caso de una paciente con CPS de presentación atípica, quien requirió fludrocortisona como opción novedosa en su tratamiento. Presentación del caso: mujer de 65 años que ingresó a urgencias por alteración en estado de conciencia, hiponatremia severa y signos vitales estables. No cursó con diarrea, emesis o fiebre. Se sospechó de síndrome de secreción inadecuada de hormona antidiurética (SIADH) y se manejó con restricción hídrica que empeoró la hiponatremia. Tras identificar hemoconcentración y poliuria se orientó el diagnóstico a CPS, lo que dirigió a tratamiento con solución hipertónica complementado con fludrocortisona, esencial para alcanzar niveles de seguridad. Finalmente, se realizó una punción lumbar que confirmó meningitis por criptococosis como origen del síndrome. Discusión y conclusión: el CPS tiene una presentación inusual y este caso demuestra que el tratamiento con fludrocortisona es útil para casos refractarios de origen infeccioso

Casos empresariales: Una visión desde la administración y competitividad

Presentamos a la comunidad académica y empresarial el libro “Casos empresariales: una visión desde la Administración y Competitividad” de la Facultad de Negocios, Gestión y Sostenibilidad y la Escuela de Administración y Competitividad de la Institución Universitaria Politécnico Grancolombiano (IUPG). Este libro recoge los casos de estudio desarrollados por estudian-tes y profesores de la Especialización en Gestión Empresarial y del programa de Administración de Empresas.Presentamos cuatro casos que reflejan situaciones problémicas propias de estos ambientes empresariales Son situaciones que requieren inicialmente de un diagnóstico para determinar las causas y consecuencias, así como, los posibles planes de mejora

Introducción

Este libro recoge los casos de estudio desarrollados por estudiantes y profesores de la Especialización en Gestión Empresarial y del programa de Administración de Empresas

Anales del III Congreso Internacional de Vivienda y Ciudad "Debate en torno a la nueva agenda urbana"

Acta de congresoEl III Congreso Internacional de Vivienda y Ciudad “Debates en torno a la NUEVa Agenda Urbana”, ha sido una apuesta de alto compromiso por acercar los debates centrales y urgentes que tensionan el pleno ejercicio del derecho a la ciudad. Para ello las instituciones organizadoras (INVIHAB –Instituto de Investigación de Vivienda y Hábitat y MGyDH-Maestría en Gestión y Desarrollo Habitacional-1), hemos convidado un espacio que se concretó con potencia en un debate transdisciplinario. Convocó a intelectuales de prestigio internacional, investigadores, académicos y gestores estatales, y en una metodología de innovación articuló las voces académicas con las de las organizaciones sociales y/o barriales en el Foro de las Organizaciones Sociales que tuvo su espacio propio para dar voz a quienes están trabajando en los desafíos para garantizar los derechos a la vivienda y los bienes urbanos en nuestras ciudades del Siglo XXI

Preliminares

Presentamos a la comunidad académica y empresarial el libro “Casos empresariales: una visión desde la Administración y Competitividad” de la Facultad de Negocios, Gestión y Sostenibilidad y la Escuela de Administración y Competitividad de la Institución Universitaria Politécnico Grancolombiano (IUPG).Este libro recoge los casos de estudio desarrollados por estudian-tes y profesores de la Especialización en Gestión Empresarial y del programa de Administración de Empresas

Profiles of Amino Acids and Acylcarnitines Related with Insecticide Exposure in Culex quinquefasciatus (Say).

Culex quinquefasciatus Say is a vector of many pathogens of humans, and both domestic and wild animals. Personal protection, reduction of larval habitats, and chemical control are the best ways to reduce mosquito bites and, therefore, the transmission of mosquito-borne pathogens. Currently, to reduce the risk of transmission, the pyrethroids, and other insecticide groups have been extensively used to control both larvae and adult mosquitoes. In this context, amino acids and acylcarnitines have never been associated with insecticide exposure and or insecticide resistance. It has been suggested that changes in acylcarnitines and amino acids profiles could be a powerful diagnostic tool for metabolic alterations. Monitoring these changes could help to better understand the mechanisms involved in insecticide resistance, complementing the strategies for managing this phenomenon in the integrated resistance management. The purpose of the study was to determine the amino acids and acylcarnitines profiles in larvae of Cx. quinquefasciatus after the exposure to different insecticides. Bioassays were performed on Cx. quinquefasciatus larvae exposed to the diagnostic doses (DD) of the insecticides chlorpyrifos (0.001 μg/mL), temephos (0.002 μg/mL) and permethrin (0.01 μg/mL). In each sample, we analyzed the profile of 12 amino acids and 31 acylcarnitines by LC-MS/MS. A t-test was used to determine statistically significant differences between groups and corrections of q-values. Results indicates three changes, the amino acids arginine (ARG), free carnitine (C0) and acetyl-carnitine (C2) that could be involved in energy production and insecticide detoxification. We confirmed that concentrations of amino acids and acylcarnitines in Cx. quinquefasciatus vary with respect to different insecticides. The information generated contributes to understand the possible mechanisms and metabolic changes occurring during insecticide exposure

Risk of COVID-19 after natural infection or vaccinationResearch in context

Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health

Risk of COVID-19 after natural infection or vaccinationResearch in context

Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health